Faktor-Faktor yang Memengaruhi Ketahanan Hidup Pasien HIV/AIDS: A review
Until now there is no vaccine that can fight HIV / AIDS. Antiretroviral Agents (ARVs) can only provide survival by slowing the reproduction of viruses. The purpose of this review is to describe the factors that can affect survival (PLWHA) after ARV administration. factors that can affect the survival / survival of people with HIV / AIDS (PLWHA) in addition to the provision of antiretroviral drugs. This review was conducted by the author in January - March 2019, by searching databases including PubMed, Google scholar, and open access science direct. In this review, it has been explained various factors that affect the survival of PLWHA who receive ARV treatment, including: Birth sex, age, nutritional status, CD4 levels and co-infection.
Brinkhof, M. W. G., Pujades-rodriguez, M. and Egger, M. (2009) ‘Mortality of Patients Lost to Follow-Up in Antiretroviral Treatment Programmes in Resource-Limited Settings?: Systematic Review and Meta-Analysis’, 4(6).
Carvour, M. L. et al. (2015) ‘Differential survival for men and women with HIV/AIDS-related neurologic diagnoses’, PLoS ONE, 10(6), pp. 1–11.
Gupta A,NadkarniG, Yang WT, et al. Early mortality in adults initiating antiretroviral therapy (ART) in low- and middle-income countries (LMIC): a systematic review and meta-analysis. PLoS One 2011;6: 271–84.
Günthard, H. F. et al. (2016) ‘Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults’, JAMA. doi: 10.1001/jama.2016.8900.
KaiserJD, Campa AM, Ondercin JP, Leoung GS, Pless RF, Baum MK. (2006)‘Micronutrient suppleme¬n-tation in-creases CD4 count in HIV-infected individuals on highly active anti-retroviral therapy: a prospective, double-blinded, placebo-controlled trial.’, Journal of acquired immune deficiency syndromes (1999), 42(5): 523–528.
Kogoya, T., Demartoto, A. and Murti, B. (2017) ‘Survival Predictors of People Living with HIV / AIDS in Wamena , Papua’, Indonesian Journal of Medicine’. pp. 184–191.
Matheron S, Pueyo S, Damond F, Simon F, Leprêtre A, Campa P, et al. Factors associated with clinical progression in HIV-2 infected-patients: the French ANRS cohort. AIDS Lond Engl. 2003 Dec 5; 17(18):2593–601.
Mfinanga SG, Kirenga BJ, Chanda DM. (2014). Early versus delayed initiation of highly active antiretroviral therapy for HIV-positive adults with newly diagnosed pulmonary tuberculosis (TB-HAART): a prospective, international, randomised, placebo-controlled trial. Lancet Infect Dis;14:563–71
Peterson I, Togun O, de Silva T, Oko F, Rowland-Jones S, Jaye A. (2011) Mortality and immunovirological outcomes on antiretroviral therapy in HIV-1 and HIV-2-infected individuals in the Gambia. AIDS Lond Engl. 25(17):2167–75.
Sterne JA, May M, Costagliola D, (2009). Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet;373:1352–63.
Tchouga B, Ekouevi D K, Balestre E dan Dabis F. (2016). ‘Mortality and survival patterns of people living with HIV-2’. Curr Opin HIV AIDS. 11(5): 537–544.
Zhang, G. et al. (2016) ‘Outcomes and factors associated with survival of patients with HIV/AIDS initiating antiretroviral treatment in Liangshan Prefecture, southwest of China: A retrospective cohort study from 2005 to 2013’, Medicine (United States), 95(27).